Topical Corticosteroids

Topical corticosteroids (TCS) are the main anti-inflammatory treatment for Atopic Dermatitis flares in toddlers and are used on top of daily Emollient Therapy, which stays the foundation of care. Potency is graded on two different scales. The UK/NZ system has four tiers: mild (Hydrocortisone, hydrocortisone acetate), moderate (2–25 times hydrocortisone: Clobetasone Butyrate, hydrocortisone 17-butyrate, triamcinolone acetonide), potent (100–150 times: betamethasone valerate, mometasone furoate, methylprednisolone aceponate) and very potent (up to 600 times: clobetasol propionate) (DermNet). The US uses seven groups, from group I “ultra-high” (clobetasol propionate 0.05%, augmented betamethasone dipropionate 0.05%) down to group VII “low” (hydrocortisone 1–2.5%), with desonide and alclometasone in group VI (AFP 2009). Strength also depends on the base: ointments penetrate more than creams of the same drug, and occlusion raises absorption several-fold (AFP 2009). A 2017 Cochrane review found TCS worked better combined with a moisturiser than alone, and the NHS advises leaving 20–30 minutes between applying an emollient and a steroid (carried over from the earlier stub).

Conflict: [AFP Cochrane for Clinicians, 2023] lists desonide 0.05–0.1% as medium potency and triamcinolone 0.1% as high potency. [AFP Ference & Last, 2009] places desonide in US group VI (low), and [DermNet, n.d.] lists triamcinolone acetonide as moderate. The same molecule can sit in different tiers depending on the classification and vehicle used. Unresolved — add to open_questions.

Topical Corticosteroids [treats] Atopic Dermatitis Emollient Therapy [supports] Topical Corticosteroids Hydrocortisone [part-of] Topical Corticosteroids Clobetasone Butyrate [part-of] Topical Corticosteroids Cochrane [supports] Topical Corticosteroids

Which potency, where, for a toddler

NICE guideline NICE CG57 (children under 12) says potency should match severity: mild for mild eczema, moderate for moderate, potent for severe. Body site matters too. On the face and neck, use mild potency only, apart from 3–5 days of moderate potency for a severe flare. In vulnerable sites such as armpits and groin (which includes the nappy area), moderate or potent preparations should be used only for 7–14 days. Very potent TCS should not be used in children without specialist advice. Potent TCS should not be used under 12 months without specialist supervision. From 12 months, if mild or moderate TCS have not controlled a flare in 7–14 days, a potent TCS may be used for up to 14 days, never on the face or neck, after checking for infection. US guidance gives the same advice in its own terms: low-potency groups VI–VII for the face, eyelids, nappy dermatitis and skin folds, and nothing from groups I–III on the face, groin or armpits, or under occlusion (AFP 2009). A nappy works like an occlusive dressing, which is why the nappy area is treated cautiously (an inference from AFP 2009’s occlusion data). NICE also asks pharmacists to put the potency label on the tube itself, not only on the outer box.

NICE [regulates] Topical Corticosteroids NICE CG57 [defines] Topical Corticosteroids Hydrocortisone [treats] Atopic Dermatitis Topical Corticosteroids [relates] Topical Calcineurin Inhibitors

How much and how often

The Fingertip Unit (FTU) is the line of cream squeezed from a standard tube along an adult index finger, from the tip to the first crease. It holds about 0.5 g (0.4 g for an adult woman’s finger) (DermNet; Long & Finlay 1991). Doses for children are still measured on an adult finger, by body area:

(Patient.info, from Long & Finlay.) On frequency, the 2022 Cochrane review (Lax et al.: 104 RCTs, 8,443 participants) found that applying potent TCS once daily is probably as effective as twice daily (15 trials, n=1,821; OR 0.97). Stronger preparations were probably more effective than weaker ones. Per 1,000 people treated, about 340–390 cleared or almost cleared with mild TCS, 460–520 with moderate and 530–710 with potent. Potent and moderate TCS did not differ significantly (OR 1.33). NICE allows once- or twice-daily application, and only to areas that are active or were active in the past 48 hours, including broken skin. DermNet’s usual regimen is once daily, usually at night, for 5 days to several weeks.

Conflict: [AFP summarising AAD 2014 guidance, 2023] says the AAD recommends twice-daily application, although once daily may be enough. [Cochrane, Lax 2022] finds once daily probably as effective as twice daily, and [NICE CG57, 2007 rec., current] allows either. The AAD’s 2023 update covers adults only. Unresolved — add to open_questions.

Fingertip Unit [defines] Topical Corticosteroids Cochrane [supports] Topical Corticosteroids

Proactive (weekend) maintenance

Once a flare is controlled, Weekend Therapy means applying TCS to the usual problem areas on two consecutive days each week to stop flares coming back. In Cochrane 2022 (7 trials, 1,149 people, mostly moderate to severe eczema), this lowered flare-ups from about 576 to 248 per 1,000 (NNT about 3), and there were no cases of skin thinning in 1,050 participants. NICE suggests it for children who have 2–3 flares a month and says to review it within 3–6 months. The AAD 2023 adult guideline recommends medium-potency TCS twice weekly as maintenance (Guideline Central summary). The American Academy of Dermatology’s topical-therapy guidance for children is still the 2014 version, pending a new paediatric guideline (JAAD 2023).

Weekend Therapy [prevents] Atopic Dermatitis Weekend Therapy [part-of] Topical Corticosteroids American Academy of Dermatology [supports] Weekend Therapy

Side effects and the evidence in children

Local effects. Skin Atrophy (thinning) is the most common side effect (AFP 2009). Others are striae, telangiectasia, easy bruising, perioral dermatitis and steroid rosacea. They mostly follow months of daily use of an unnecessarily potent TCS (DermNet). In Cochrane 2022, 22 studies (2,266 people) found 26 possible cases of skin thinning: 16 with very potent TCS, 6 with potent, 2 with moderate and 2 with mild. TCS can also mask or worsen infections such as impetigo, tinea and herpes simplex, although TCS are still first-line for infected eczema (DermNet).

Systemic effects. The Axon 2021 umbrella review (38 reviews, 34 of them low or critically low quality) pooled 11 uncontrolled studies in 522 children. It found biochemical HPA Axis Suppression (low cortisol) in 3.8% (95% CI 2.4–5.8%), which reversed when treatment stopped. It found no evidence of growth suppression and no evidence of harm with as-needed or weekend use. One RCT, however, found biochemical suppression in 2 of 44 children on potent weekend therapy. DermNet says Cushing-type effects occur only after long-term use of large amounts (for example more than 50 g a week of clobetasol), usually from misuse or over-the-counter sales.

Conflict: [DermNet, n.d.] says systemic effects are rare and need very large long-term quantities (>50 g clobetasol/week). [Axon et al., BMJ Open 2021] reports biochemical adrenal suppression in 3.8% of children across studies of TCS of any potency, plus 2/44 children on potent weekend therapy. Both agree the effect is reversible. They disagree on how often subclinical suppression happens at ordinary doses. Unresolved — add to open_questions.

Undeclared steroids in "natural" creams

Creams sold as “natural”, herbal or “steroid-free” eczema remedies can contain undeclared corticosteroids, sometimes potent ones. A toddler could then get potent steroid on the face or in the nappy area with no potency label and no time limit, which is exactly the misuse linked to atrophy, adrenal suppression and withdrawal reactions. Only use prescribed or pharmacy-labelled TCS with a known potency.

Topical Corticosteroids [causes] Skin Atrophy Topical Corticosteroids [causes] HPA Axis Suppression

Steroid phobia and the Topical Steroid Withdrawal debate

Steroid Phobia is fear of TCS, and it is widespread among parents. A systematic review of 16 cross-sectional studies found a prevalence of 21.0% to 83.7%. Patients with phobia were less adherent to treatment (non-adherence 49.4% vs 14.1%, and 29.3% vs 9.8%), and much of the misinformation came from doctors, relatives, the media and the internet (Li et al., JAMA Dermatology 2017). In a 2021 survey of 301 parents in Taif (published 2023), Saudi Arabia (TOPICOP scale), the median phobia score was 66.6%. In that survey, 70.5% were afraid of TCS without knowing its side effects, 21.6% did not follow the doctor’s instructions, and 44.5% had stopped TCS over side effects they had seen. NICE tells clinicians to explain that the benefits outweigh the harms when TCS are used correctly. Topical Steroid Withdrawal (TSW, “red skin syndrome”) is the main reason behind recent online concern. Hajar et al. (JAAD 2015, 34 studies, GRADE very low) concluded it is “likely a distinct clinical adverse effect of TCS misuse”. In that review it was reported mostly on the face and genitals of adult women after long-term use of inappropriately potent TCS. Ahuja & Lio (Pediatric Dermatology 2025) found only 21 published paediatric cases, aged 8 months to 16 years. Every case with data had at least 3 months of continuous use, 69% had escalated potency and 60% had used TCS on the face. The authors propose TSW as a diagnosis of exclusion and say its mechanism is unknown. The 2024 Cochrane network meta-analysis could not evaluate TSW.

Conflict: [Axon et al., BMJ Open 2021] and [Cochrane, Lax 2022] found no evidence of harm from intermittent or weekend TCS use. [Ahuja & Lio, Pediatric Dermatology 2025] report paediatric TSW cases whose use patterns ranged “from multiple daily applications to twice-weekly use”. Whether low-frequency maintenance carries any TSW risk in toddlers is unclear: trials were short and the case reports are sparse and poorly documented. Unresolved — add to open_questions.

Steroid Phobia [opposes] Topical Corticosteroids Steroid Phobia [worsens] Atopic Dermatitis Topical Steroid Withdrawal [relates] Steroid Phobia Topical Corticosteroids [causes] Topical Steroid Withdrawal

What parents report (evidence: anecdotal). Across round-10 threads, a prescription steroid is the treatment parents most often say “helped the most”, often within days (r/beyondthebump; Mumsnet). Common complaints are relapse soon after stopping and fixed on/off schedules that “by the time we get her skin under control it’s time for off period”. Parents also report being given steroids too weak to clear the skin. Steroid fear is everywhere, and several parents regret it: “I waited too long as I was scared of steroid withdrawal and my baby suffered” (r/ScienceBasedParenting). Qualitative studies find forum discussions of steroids “likely to amplify existing concerns” (Teasdale et al. 2017, qualitative study). See Parent Experiences.

Topical Corticosteroids [relates] Parent Experiences

Connections

• Atopic Dermatitis — first-line anti-inflammatory treatment for flares, source: NICE CG57; Cochrane 2022
• Emollient Therapy — used alongside; emollients reduce steroid need, source: Cochrane 2017; NHS
• NICE — CG57 sets potency by site/severity and age limits for children, source: NICE CG57
• NICE CG57 — recommendations 1.5.1.12–1.5.1.20 on TCS in under-12s, source: NICE CG57
• Cochrane — Lax 2022 review on potency, frequency and weekend therapy, source: CD013356
• American Academy of Dermatology — 2023 adult topical guideline; recommends twice-weekly maintenance, source: JAAD 2023
• Hydrocortisone — mild-potency TCS used on toddler face and nappy area, source: DermNet; AFP 2009
• Clobetasone Butyrate — UK moderate-potency TCS, source: DermNet
• Fingertip Unit — dosing measure with age-banded amounts, source: DermNet; Patient.info
• Weekend Therapy — proactive maintenance cutting flares (NNT≈3), source: Cochrane 2022
• Skin Atrophy — most common local side effect, mainly with potent/very potent, source: Cochrane 2022; AFP 2009
• HPA Axis Suppression — reversible biochemical suppression in ~3.8% of children, source: Axon 2021
• Steroid Phobia — 21–84% prevalence; lowers adherence, source: Li 2017; Taif 2023
• Topical Steroid Withdrawal — contested adverse effect after prolonged potent use, source: Hajar 2015; Ahuja & Lio 2025
• Topical Calcineurin Inhibitors — NICE second-line steroid-sparing option from age 2, source: NICE CG57
• Th2 Immune Response — broad suppression of type 2 inflammation, source: Elias & Wakefield 2011
• Herbal and Home Remedies for Eczema — steroid fear drives CAM use; ‘herbal’ creams found to hide potent steroids, source: Johnston 2003; MHRA 2018
• Adulterated Herbal Creams — potent/very potent TCS found undeclared in ‘herbal’ creams, source: Ramsay ADC 2003; Keane BMJ 1999; MHRA 2018
• Perioral Dermatitis — facial/inhaled steroid exposure in 58–72% of paediatric cases, source: DermNet 2018
• Nappy Rash — low-potency TCS indicated; nappy occlusion raises absorption, source: AFP 2009; emc PIL 3807
• Eczema Prognosis — no evidence TCS worsen long-term course or cause asthma, source: Moret 2013; Illi 2004
• Treatment Outcomes Comparison — Track B anti-inflammatory core, source: Cochrane Lax 2022
• Parent Experiences — parent reports (anecdotal), source: round-10 forum threads
• Eczema in Skin of Colour — pale patches usually from eczema not steroids; steroid hypopigmentation more visible on dark skin, source: NES; Sarkar 2026
• Scabies — TCS can mask scabies (‘incognito’), source: Siegfried & Hebert 2015
• AAD Pediatric Guideline 2026 — strong rec; low potency for young children; maintenance up to 3×/week, source: JAAD 2026